AERI
Aerie Pharmaceuticals, Inc.
Set alert
52-week range unavailable
- Open
- 15.24
- Prev close
- 15.25
- Mkt cap
- 753.62M
- Vol
- 1.22M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.24
- High
- 15.25
- Forward P/E
- -13.86
- Beta
- -0.06
- Short ratio
- 1.91
- Inst. own
- 102.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2022
- 50-d avg
- 15.19
- 200-d avg
- 10.24
- 1y target
- 15.35
Key statistics
- Market cap
- 753.62M
- Enterprise value
- 918.14M
- Trailing P/E
- 0.00
- Forward P/E
- -13.86
- PEG ratio
- 0.07
- Price / sales
- 3.52
- Price / book
- 0.00
- EPS (TTM)
- -1.47
- Beta
- -0.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -17.09%
- Revenue (TTM)
- 213.94M
- Revenue growth
- 23.30%
- Free cash flow
- 1.83M
- Total cash
- 172.46M
- Total debt
- 336.99M
- Return on equity
- 0.00%
- Shares outstanding
- 49.42M
- Short % of float
- 3.13%
- 50-day average
- 15.19
- 200-day average
- 10.24
Analyst view
Consensus: hold
- Target (low)
- 6.00
- Target (mean)
- 15.35
- Target (high)
- 25.00
- Strong buy3
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2022
Expected Nov 3, 2022. Consensus EPS estimate -0.43.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2022 | Sep 1, 2022 | -0.42 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.52 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.65 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -0.68 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.62 | — | — | — |
| Aug 4, 2021 | Jun 1, 2021 | -0.65 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 29, 2022 | Citigroup | down | Buy | Neutral |
| Aug 24, 2022 | Truist Securities | down | Buy | Hold |
| Aug 24, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 23, 2022 | Stifel | down | Buy | Hold |
| Aug 23, 2022 | Needham | down | Buy | Hold |
| Aug 23, 2022 | Cantor Fitzgerald | down | Overweight | Neutral |
About Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- aeriepharma.com
News
- Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
- Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
- Earnings Scheduled For August 4, 2022
- Stocks That Hit 52-Week Lows On Thursday
- Earnings Scheduled For May 5, 2022
- 93 Biggest Movers From Friday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Tuesday
- Earnings Scheduled For November 4, 2021
- 48 Biggest Movers From Yesterday
Your note
Sign in to keep a note on AERI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CALABRESE JEFFREY | Officer | Stock Award(Grant) | Jun 30, 2022 | 19,295 |
| CROARKIN RICHARD | Director | Stock Award(Grant) | Jun 8, 2022 | 16,095 |
| DU TOIT MICHAEL | Director | Stock Award(Grant) | Jun 8, 2022 | 16,095 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | Jun 8, 2022 | 13,491 |
| KOPCZYNSKI CASEY C | Officer | Stock Award(Grant) | Mar 17, 2022 | 280,244 |
| LANG PETER FREDERICK | Chief Financial Officer | Stock Award(Grant) | Mar 17, 2022 | 46,297 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 9.82% | 4,855,005 | 74.04M | Sep 29, 2022 |
| Blackrock Inc. | 7.17% | 3,544,947 | 54.06M | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 4.94% | 2,441,120 | 37.23M | Sep 29, 2022 |
| UBS Group AG | 4.87% | 2,405,832 | 36.69M | Sep 29, 2022 |
| Jefferies Group LLC | 4.78% | 2,361,000 | 36.01M | Sep 29, 2022 |
| Water Island Capital, LLC | 4.21% | 2,082,516 | 31.76M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.92% | 1,445,441 | 22.04M | Jun 29, 2022 |
| Arbitrage Fund | 2.30% | 1,136,386 | 17.33M | Aug 30, 2022 |
| iShares Russell 2000 ETF | 2.11% | 1,044,068 | 15.92M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.32% | 650,497 | 9.92M | Jun 29, 2022 |
| Columbia Fds Var Ser Tr II-Columbia Var Port-Overseas Core Fd | 1.09% | 540,033 | 8.24M | Jun 29, 2022 |
| IndexIQ Tr-IQ Merger Arbitrage ETF | 0.94% | 463,978 | 7.08M | Oct 30, 2022 |